Fluticasone propionate

Generic Name: Fluticasone propionate

Brand Names: Advair, Airduo, Airduo Respiclick, Aller-flo, Armonair, Beser, Cutivate, Dymista, Flonase, Flovent, Fluticare, Ticanase, Wixela, Xhance

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₁F_₃O_₅S

CAS Number: 80474-14-2

Unique Ingredient Identifier: O2GMZ0LF5W

Background: Fluticasone propionate is a synthetic glucocorticoid. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications. Fluticasone propionate was first approved in 1990.

Indication: Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisas well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis.

Associated Conditions: Allergic Rhinitis (AR), Allergy to Animal Dander, Allergy to Mold, Allergy to Tree Pollen, Asthma, Bacterial Sinusitis, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Chronic Sinusitis, Dermatitis, Emphysema, Eosinophilic Esophagitis, House Dust Mite Allergy, House dust allergy, Itching of the nose, Nasal Congestion, Non-Allergic Rhinitis, Rhinitis, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Moderate, severe Perennial Allergic Rhinitis (PAR), Moderate, severe Seasonal Allergic Rhinitis

Clinical Trials

Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes.

Phase 4

Completed

Conditions: COPD

Interventions: Drug: Fluticasone Furoate/Vilanterol 100/25 mcgs
Drug: Umeclidinium/Vilanterol 62.5/25 mcgs

First Posted Date: 2022-04-22

Last Posted Date: 2022-04-22

Lead Sponsor: National Institute of Respiratory Diseases, Mexico

Target Recruit Count: 133

Registration Number: NCT05342558

Locations: 🇲🇽
National Institute of Respiratory Diseases 'Ismael Cosío Villegas', Mexico City, Tlalpan, Mexico

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis

Phase 4

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: olopatadine hydrochloride ophthalmic solution 0.7%)
Drug: Fluticasone Propionate
Drug: Saline nasal spray
Drug: Tears Naturale

First Posted Date: 2022-04-06

Last Posted Date: 2022-09-02

Lead Sponsor: Andover Research Eye Institute

Target Recruit Count: 61

Registration Number: NCT05314621

Locations: 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States

Effect of Novel Exhalational Delivery System with Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)

Phase 2

Recruiting

Conditions: Eustachian Tube Dysfunction

Interventions: Drug: Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray
Other: Placebo Nasal Spray

First Posted Date: 2022-03-11

Last Posted Date: 2025-02-12

Lead Sponsor: Cedars-Sinai Medical Center

Target Recruit Count: 80

Registration Number: NCT05275686

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
Sacramento Ear, Nose & Throat, Sacramento, California, United States

and more 1 locations

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Device: Stiolto Respimat
Device: Trelegy Ellipta
Drug: Tiotropium + Olodaterol (5/5 mcg)
Drug: Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)

First Posted Date: 2021-12-27

Last Posted Date: 2023-10-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 9117

Registration Number: NCT05169424

Locations: 🇺🇸
eMax health, White Plains, New York, United States

Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients

Completed

Conditions: Allergic Rhinitis

Interventions: Drug: Dymista

First Posted Date: 2021-12-15

Last Posted Date: 2023-11-13

Lead Sponsor: Mylan Inc.

Target Recruit Count: 924

Registration Number: NCT05158972

Locations: 🇭🇰
Asia Priority Healthcare, Kowloon, Hong Kong
🇲🇾
Kempas Medical Center, Johor Bahru, Malaysia
🇲🇾
University Malaya Medical Centre, Kuala Lumpur, Malaysia

and more 30 locations

Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial

Phase 3

Completed

Conditions: Eosinophilic Esophagitis

Interventions: Drug: APT-1011
Drug: Placebo oral tablet

First Posted Date: 2021-10-19

Last Posted Date: 2023-09-21

Lead Sponsor: Ellodi Pharmaceuticals, LP

Target Recruit Count: 6

Registration Number: NCT05083312

Locations: 🇦🇺
Royal Children's Hospital, Melbourne, Victoria, Australia
🇺🇸
IU School of Medicine Department of Pediatrics, Indianapolis, Indiana, United States
🇺🇸
Boston Specialists, Boston, Massachusetts, United States